Management team

Leading our highly qualified and experienced team

Domainex offers a unique blend of the best brains, skills and technologies in medicines research. Our people are our key asset, with an unrivalled depth and breadth of experience across drug discovery.

Tom Mander Tom Mander DPhil MBA
CEO
Tom Mander

Tom Mander DPhil MBA

CEO

Dr Tom Mander has nearly 30 years of small molecule drug discovery and translational research experience in both scientific and commercial roles. After graduating and working at Amersham International plc developing radioimmunoassays, he completed his DPhil studies with Professor John Morris into the roles of microglial cells at the Department of Human Anatomy, University of Oxford in 1992. He undertook scientific research positions with the natural product drug discovery company Xenova on a macrophage activation project partnered with Suntory in Japan and then with the Centre for Natural Product Research in Singapore. In 1995, Tom joined Glaxo Wellcome as group leader for cell-based HTS, working with therapeutic groups across Glaxo Wellcome sites and helping to discover a number of starting points for lead optimisation. In 1999, Tom joined EVOTEC BioSystems GmbH as a Bereichsleiter where he was part of the leadership team that initiated the drug discovery services business of the company. In 2003 he became Vice President of Business Development tasked with forging integrated drug discovery alliances. In 2005, he joined the leadership team of Tripos Discovery Research as Vice President of Business Development, overseeing the expansion of the business offerings and its ultimate trade sale. Tom joined Asterand plc in 2007, to promote the use of consented human biospecimens in drug discovery, biomarker research and in vitro diagnostics. In 2010, Tom was promoted to the Executive Leadership team and was based out of South San Francisco with global responsibility for sales and marketing before the trade sale of the business. Prior to joining Domainex, Tom undertook a business development assignment at Biofocus (now part of Charles River Laboratories) and was named a Top Performer in 2014.

Tom joined Domainex in April 2015 as Chief Operating Officer to oversee the scientific service operations and business development activities of the company. During his time in this role, he has established a broad portfolio of pharma, biotech, academic and patient foundation clients both in the UK and overseas, launched several new services and has overseen the growth of the company.

In April 2020, he took over as Chief Executive Officer after the retirement of Dr Trevor Perrior.

Barry Knight Barry Knight
CFO and Company Secretary
Barry Knight

Barry Knight

CFO and Company Secretary

Barry Knight is a Chartered Accountant with more than thirty years’ experience as Finance Director, Chief Financial Officer and Chief Operating Officer with companies operating in the Life Sciences sector.

He first worked with Domainex in 2014 as a consultant and later joined the management team as part-time CFO and Company Secretary, returning to that role in 2019 after a brief spell as part-time CFO for Small Pharma, a London-based biotech. Since 2015, Barry has also been part-time CFO and Company Secretary for Edinburgh Molecular Imaging, a biotech company developing a molecular targeted systemic radiotherapy treatment.

After graduating from the University of Bristol with a BSc in Physics, he qualified as a Chartered Accountant with Josolyne Layton Bennett, a predecessor firm of Ernst & Young and then moved into commerce and industry, joining the head office of Cope Allman International plc, holding a number of finance roles and ultimately being appointed Group Chief Accountant in 1985.

In 1989 he made the move into Life Sciences, becoming Finance and Administration Director of KeyMed, one of the UK’s biggest suppliers of medical equipment, seeing it through ten years of significant growth before joining Trigen, a biotechnology start-up in the cardiovascular field, in 2000.

Barry has subsequently worked for two consultancies serving the Life Sciences sector, as Chief Operating Officer for Kinapse Ltd and as Finance Director for AIM-listed Fulcrum Pharma plc.

Ray Boffey Ray Boffey PhD
Head of Chemistry
Ray Boffey

Ray Boffey PhD

Head of Chemistry

Dr. Ray Boffey has over 20 years’ drug discovery experience in CRO and biotech companies. He joined Domainex in 2010, having previously worked at Lectus Therapeutics where he focused on ion-channel drug discovery programmes. Prior to that, Ray led medicinal chemistry teams working on behalf of global pharma companies at Argenta Discovery after starting his career at Oxford Glycosciences.

Over his career Ray has directed programmes from hit identification through to candidate nomination tackling a wide range of biological targets including protein-protein interactions, ion-channels, GPCRs, enzymes (iNOS, caspase, PARP, and kinases) and integrins. These programmes cover therapeutic areas such as oncology, inflammation (including asthma and COPD), Parkinson’s disease, stroke, circadian rhythms, anti-fungal project and pain. As a result, Ray is a named inventor and author of numerous patents and publications.

Ray conducted his post-doctoral research at Imperial College, working with Professor A. G. M Barrett FRS and obtained his PhD from the University of Southampton in 1999, where he researched the ‘Diastereoselective samarium(II) iodide-mediated cascade radical cyclisations of methylenecyclopropane derivatives’ and synthesised the natural product (±)-Paeonilactone B with Professor Jeremy Kilburn.

Stefanie Reich Stefanie Reich PhD
Head of Protein Science
Stefanie Reich

Stefanie Reich PhD

Head of Protein Science

Dr. Stefanie Reich joined Domainex in 2006 and leads the Protein Science Group. She has successfully managed over 50 internal and client-based projects, using a range of techniques, including gene design, molecular biology, protein expression and purification and structural analysis. Stefanie was a key member of the team that developed Combinatorial Domain Hunting (CDH) and is an expert in its application to difficult protein expression problems. She has worked on a wide range of proteins including kinases, epigenetic targets, transcription factors, proteases and protein-protein interactions.

Stefanie obtained her PhD from the Humboldt University Berlin, working with Prof Detlev Krüger at the Humboldt University Charité Medical School (Berlin, Germany), where she studied protein-DNA interactions, using techniques including electron microscopy and atomic force microscopy. She conducted her post-doctoral research at Birkbeck College (London, UK).

Trevor Askwith Trevor Askwith PhD
Head of Assay Biology
Trevor Askwith

Trevor Askwith PhD

Head of Assay Biology

Dr Trevor Askwith is a Group Leader in assay biology with over 10 years’ experience of small-molecule drug discovery research. Prior to joining Domainex, Trevor held the role of Head of Assay Development and Screening in the Drug Discovery Group at UCL, where he ran a number of successful hit ID for novel targets emerging from the university. Before joining UCL, Trevor was a Senior Research Fellow in the Drug Discovery Centre at the University of Sussex where he helped to establish the facility as well as develop and run cell-based and biochemical screening assays to support Welcome Trust and CRUK funded projects. Trevor began his career at Novartis respiratory division working on projects supporting for idiopathic pulmonary fibrosis and pulmonary arterial hypertension.

Trevor obtained his PhD from the University of Birmingham working with Prof Martin Stevens where he studied the mechanisms of taurine depletion in diabetic neuropathy. He has a broad experience of biochemical and cellular assays, high throughput screening and both ‘conventional’ and fragment-based research projects and has worked on many different target classes and therapeutic areas.

Steve Lloyd Steve Lloyd
Principal Research Leader, Analytical Chemistry
Steve Lloyd

Steve Lloyd

Principal Research Leader, Analytical Chemistry

Steve Lloyd is a highly-experienced analytical chemist who leads the Domainex Analytical Team. Previously he was a Principal Analytical Scientist for over 8 years in the Analytical Research and Development group at UCB R&D (formally Celltech Chiroscience) and was responsible for the development of numerous analytical methods in support of pre-clinical and clinical candidates. Prior to this he worked at Pfizer, Sandwich, as an analytical scientist in the Analytical R&D department.

With nearly 25 years’ experience in drug discovery, Steve has worked on a number of different R&D projects and a range of biological targets including; Der p 1 protease, TANK-binding kinase 1 (TBK1) IkappaB kinase epsilon (IKKε), phosphoinositide 3 kinase (PI3K), matrix metalloproteinases (MMP), interleukin-1 receptor associated kinase (IRAK), inosine 5'-monophosphate dehydrogenase (IMPDH), Inositol-1-phosphatase, P2Y2 receptors, PPIs, phosphodiesterase IV (PDE IV) and phosphodiesterase VII (PDE VII) inhibitors as well as a number of protein-protein interaction targets.

Philip Fallon Philip Fallon PhD
Group Leader, Chemistry
Philip Fallon

Philip Fallon PhD

Group Leader, Chemistry

Dr Philip Fallon is a Group Leader in medicinal chemistry with 20 years’ industrial experience of small-molecule drug discovery research. Prior to his ten years’ at Domainex, Philip held research positions at BioFocus, Medivir, and Aventis and Rhone-Poulenc CropScience.

Philip has worked successfully in all stages of drug discovery, from early hit identification through to lead optimisation. He is a named inventor on several patents, has presented research at international conferences and was part of the project team which invented MIV-711, a Cathepsin K inhibitor, currently in Ph II clinical trials for osteoarthritis. During his career, Philip has gained experience in several therapeutic areas (oncology, anti-coagulants, liver disease) and target classes (proteases, protein-protein interactions including RAS, neuropilin and lysine methyltransferases).

Philip graduated from the University of Cambridge and obtained his PhD from Nottingham University working under the supervision of with Dr Mark Mascal.Image removed.

Andrew Ratcliffe Andrew Ratcliffe PhD
Group Leader, Chemistry
Andrew Ratcliffe

Andrew Ratcliffe PhD

Group Leader, Chemistry

Dr Andrew Ratcliffe ‘AJ’ is a Group Leader in medicinal chemistry with over 30 years’ of drug discovery gained across large pharma and biotech companies. AJ has worked successfully in all stages of drug discovery, from early hit identification through to candidate nomination. Prior to joining the Domainex team, AJ has worked at Rhone Poulenc Rorer, Celltech, UCB, Cellzome, Redx Anti-infectives and Novintum Bioscience. During this time, he has taken leadership roles in delivering research projects, cumulating in the nomination of multiple small molecule candidates in the areas of RA (two JAK kinase inhibitors), oncology (mitochondrial disruptor) and MS (two VLA4 integrin antagonists). The VLA4 integrin antagonist, CDP323, was progressed to phase II clinical trials in MS.

Other key areas of research have focused on PDEIV inhibitors, IMPDH inhibitors, JNK and PI3K delta kinase inhibitors (which ultimately led to the identification and progression of UCB5857 into clinical trials), and DNA Gyrase inhibitors as anti-bacterial agents (which led to European funding through the ENABLE initiative). AJ has experience in IP management and was a proactive committee member within the Society of Medicines, a multi-disciplinary society engaged in promoting drug research.

AJ completed his first degree and PhD at the University of Bath under Dr Malcolm Sainsbury, followed by a SERC NATO Postdoctoral Fellowship at Duke University, North Carolina, USA with Professor Bert Frasier-Reid. AJ has over 70 publications covering peer reviewed papers and patents.

Natalie Winfield Natalie Winfield PhD
Products and Contracts Manager
Natalie Winfield

Natalie Winfield PhD

Products and Contracts Manager

Dr. Natalie Winfield joined Domainex in 2005 and was a Team Leader in Medicinal Chemistry prior to transitioning into the role of Products and Contracts Manager. During her time as a Team Leader Natalie managed multiple client research projects and gained experience of a wide range of biological targets including protein-protein interactions, kinases, proteases, methyl transferases and phosphodiesterases. Natalie’s scientific background enables her to interact well with our clients at a technical level, and to offer commercial support for the full range of services that Domainex offers.

Natalie graduated from the University of Bristol and also obtained her PhD there, working under the supervision of Professor Tom Simpson FRS and Professor Chris Willis.

Catherine Stace PhD Catherine Stace PhD
Director of Business Development
Catherine Stace PhD

Catherine Stace PhD

Director of Business Development

Dr Catherine Stace ‘Cat’ has 14 years’ experience in therapeutic discovery and health-tech, gained at companies such as XenoVida, Cancer Targeting Systems, Bicycle Therapeutics and Isogenica. Prior to joining Domainex in 2019, Cat ran her own consultancy business providing technology advice to early-stage biotech companies, focusing on the strategic design of technology platforms to support commercial growth and innovation.

Cat began her career at Isogenica in 2006, where she developed novel cell-based applications of the platform technology and participated in therapeutic discovery projects. Cat joined Bicycle Therapeutics in 2010 as one of the original team responsible for establishing & optimising their industrial discovery platform. She is a named inventor on patents for core technology and clinical candidates, and led the Phage Display team 2014-16. Collectively, Cat has worked on over 30 therapeutic programmes across a wide range of target classes, in many cases leading hit id & hit-to-lead projects and contributing to downstream development strategies.

Cat obtained her PhD in Cell Biology from the University of Cambridge (Babraham Institute), graduated from Nottingham with an MSci in Biochemistry, and is a certified Systems Engineer (INCOSE).

Trevor Perrior PhD Trevor Perrior PhD
Scientific Consultant
Trevor Perrior PhD

Trevor Perrior PhD

Scientific Consultant

In an industrial career spanning 35 years, Dr Trevor Perrior has led drug discovery teams that have delivered numerous development candidates across several therapeutic areas. Following his education at the University of Cambridge Trevor undertook academic research at Cambridge, Oxford and in the USA. He then held a number of senior R&D leadership roles in the pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, USA, and Switzerland.

In 2005 Trevor joined NCE Discovery as Chief Scientific Officer, and when NCE Discovery merged with Domainex he became Director of Research for the enlarged company. In 2016 he was appointed Chief Scientific Officer of Domainex, and then in 2018 Chief Executive Officer. In April 2020, Trevor retired from this role, but continues to support Domainex as a scientific consultant. Trevor is also a scientific consultant to a number of venture capital and charitable funds.